Dysregulation in the KYN pathway, particularly the over-expression of the IDO1, TDO2 and KMO enzymes, has been extensively shown to be associated with the progression of various cancers, including breast25,59, colorectal60, glioblastoma61 and liver cancer62. The gene discussed is KMO; the disease is cancer.